Eli Lilly and Novo Nordisk Agree to Cut Weight-Loss Drug Prices in U.S. Deal

This article first appeared on GuruFocus.

Eli Lilly (LLY, Financials) and Novo Nordisk (NOV, Financials) have agreed to slash prices on their weight-loss drugs in a deal with the Trump administration, aiming to make the treatments more affordable for Medicare and Medicaid patients.

Warning! GuruFocus has detected 6 Warning Signs with NVDA. Is LLY fairly valued? Test your thesis with our free DCF calculator.

Under the plan, starter doses of upcoming oral GLP-1 drugs will cost $149 per month for government programs and cash payers through the new TrumpRx platform. Injectable versions, including Lilly's Zepbound and Novo's Wegovy, will be priced at $245 per month for Medicare and Medicaid patients, with co-pays capped at $50.

President Donald Trump said the move would help equalize the world on drug costs, noting that Americans often pay triple what patients in other developed countries spend.

Analysts estimate the new pricing could unlock access for up to 15 million Americans, potentially reshaping a $100 billion obesity treatment market.

View Comments